Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tecentriq and Radiotherapy in Recurrent/Refractory SCLC
NCT03262454Phase 2Unknown
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jan 2018
- Primary completion
- Feb 2023
- Countries
- 1
01
Overview
Phase 2, open-label trial of atezolizumab in small cell lung cancer (SCLC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Objective Response Rate at 1 year. Status: unknown.
02
Drugs
atezolizumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03262454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03262454.